Peptavo is Accredited for 20 CME hours.Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
PEPTAVO
The Stack Source LLC1908 E 11th Street Austin, TX 78702support@peptavo.com(512) 827-8158DBA: Peptavo
Peptavo is Accredited for 20 CME hours.Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
Get volume discounts if you are getting 3 or more clinicians certified
Book a Call
A doctor cannot lawfully prescribe, administer, or dispense a research use only peptide, and the label does not change that. FDA judges a product by its intended use, and boards in Alabama, Mississippi, and South Carolina have said so in writing. Here is the rule, the notices, and what you can prescribe.
No. A doctor cannot lawfully prescribe, administer, or dispense a "research use only" peptide to a patient, and the label on the vial does not change that. FDA treats any product sold for human use as a drug whatever the label says, and boards in three states have now told their licensees in writing that research grade peptides have no place in patient care.
That answer surprises clinicians who see the same peptide sold as lab powder online and as a prescription product in a clinic. The difference is not the molecule. It is who made it, under what standard, and for whom. This guide covers the federal rule, what the Alabama, Mississippi, and South Carolina boards said, why a prescription or a signed waiver does not fix the problem, and what you can prescribe instead.
Status as of October 22, 2026. The Alabama Board of Medical Examiners issued its notice in May 2026, the Mississippi boards on August 19, 2026, and the South Carolina Board of Medical Examiners in August 2026. FDA sent warning letters to online sellers in March and August 2026.
The phrase is a label a seller prints, not a regulatory status. It tells you the seller does not claim the product is for people. It is not an FDA approval, and it is not a compounding pathway. A research use only vial is not an approved drug, and it is not a preparation made by a licensed pharmacy for an identified patient.
The Alabama Board of Medical Examiners puts the clinical problem plainly: these substances are "not subject to regulation or oversight by the FDA regarding safety, efficacy, or manufacturing standards and consistency," so neither the provider nor the patient can "verify the contents of any vials." The American Medical Association raised the same point in its April 29, 2026 guide for patients on injectable peptides, where a sports medicine physician warned that products sold through wellness spas, online sites, and the grey market carry added risks of contamination, sourcing, and dosing.
Under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act, a product is a drug when it is intended to diagnose, treat, or prevent disease, or to affect the structure or function of the body. Under 21 CFR 201.128, FDA reads that intent from labeling claims, advertising, and the circumstances surrounding distribution, including a use the product is "neither labeled nor advertised" for but is offered or used for. A new drug may not be sold across state lines without an approved application under section 505(a).
FDA has applied that test to the "research use only" disclaimer directly. In a March 31, 2026 warning letter, the agency wrote that despite labels marketing the products for "Research Use Only" and "not intended for human consumption, medical use, or veterinary use," evidence from the seller's website "establishes that your products are intended to be drugs for human use." In letters dated August 24, 2026, FDA added that selling bacteriostatic water for reconstitution supplies "the means to prepare an injectable drug for human administration."
Those letters went to sellers, not prescribers. But the reasoning is the one that makes a clinician's involvement hard to defend. Once a physician recommends, supplies, or injects the vial, a "research only" intent is very hard to claim.
Three boards have addressed research grade peptides directly in 2026. Their notices share most of their language.
| Board | Issued | Who it covers | What it says |
|---|---|---|---|
| Alabama Board of Medical Examiners | May 2026 | Physicians, and delegation to CNMs, CRNPs, and PAs | No physician may compound, administer, or dispense a research grade peptide. No such peptide is on any approved NP or PA formulary. |
| Mississippi joint statement (medical licensure, nursing, and pharmacy boards) | August 19, 2026 | Every healthcare provider | No provider may compound, administer, or dispense one. Drugs and ingredients must come from entities the Board of Pharmacy permits. |
| South Carolina Board of Medical Examiners (content as summarized by the American Med Spa Association) | August 2026 | Physicians, and delegation to APRNs and PAs |
Four points run through all three notices.
The ban reaches past prescribing. Alabama and Mississippi both say the prohibition includes advising, recommending, supplying, prescribing, and administering. A physician who only recommends a source has still crossed the line.
Delegation does not help. Alabama states that a physician "may not circumvent his or her duty of care to patients by permitting or delegating" these steps to NPs or PAs, and South Carolina extends its notice to APRNs and PAs. For the NP side of the question, see our guide on whether nurse practitioners can prescribe peptides.
A waiver does not help either. Alabama says consent forms "purporting to identify a product as 'research-grade' are ineffective and do not mitigate or eliminate the health care provider's professional or legal liability." Mississippi and South Carolina say the same.
A patient's own purchase is the patient's risk, up to a point. Alabama and Mississippi both say that when a patient acquires and self-administers one of these products independently, the risk rests with the patient, but "any involvement by a medical professional in recommending, supplying, prescribing, or administering these substances constitutes the practice of medicine and is prohibited."
One drafting detail deserves a read from your own board or counsel. Alabama's notice bars compounding, administering, or dispensing "a non-FDA approved or research grade peptide," Mississippi's uses nearly identical wording, and every compounded drug is technically not FDA approved. Read with Alabama's requirement that drugs be prescription quality and both states' requirement that drugs come from entities the Board of Pharmacy permits, the notices aim at research grade products, not at licensed pharmacy compounding. The wording is still broad, so confirm how your board reads it before you rely on a compounded source.
Other boards have not issued research grade notices that we could find, and Louisiana has gone the other way on lawful sources: Act 374, effective August 1, 2026, bars licensing boards from prohibiting prescribers from providing peptides shipped from a compliant 503A pharmacy or a registered 503B outsourcing facility. A board that has not spoken has not approved the practice, and the federal analysis applies in every state.
A prescription is an order to a pharmacy, and the pharmacy has to be able to fill it lawfully. For a compounded peptide, section 503A requires each bulk drug substance to meet an applicable USP or NF monograph, or be a component of an FDA-approved drug, or appear on a list FDA develops. It must also be manufactured by an establishment registered with FDA and come with a valid certificate of analysis (21 U.S.C. 353a). Being sold as "research use only" satisfies none of those routes by itself, and a physician who compounds on site is held to the same conditions.
Our guides on the FDA compounding categories and on 503A and 503B pharmacies show which bulk substances qualify today, and the compounding pharmacy vetting checklist covers how to check the pharmacy itself.
The same peptide name can appear in three very different legal products.
| Research use only | Compounded (503A) | FDA-approved | |
|---|---|---|---|
| Made by | A chemical supplier | A state-licensed pharmacy | A drug manufacturer |
| Made for | No identified patient, labeled not for human use | One identified patient, on a prescription | The labeled indication |
| Oversight | No FDA or pharmacy board standards for manufacturing or contents | State board of pharmacy, with FDA surveillance | FDA application and inspection |
| Bulk substance rules | None attached to the label | Must meet section 503A | Not applicable |
| Can a clinician prescribe or administer it | No | Yes, if the bulk substance qualifies and your board allows it | Yes, on or off label under state law |
This is the common case, and the boards draw the line at recommending, supplying, prescribing, and administering. Counseling a patient on the risks of a product they obtained themselves, documenting the conversation, and offering a lawful alternative sits on the other side of that line. Ask counsel before you adjust, monitor against, or endorse a self-sourced regimen.
Chart what the patient reports using, the risks you discussed, and the lawful options you offered. Our conversation openers guide covers how to raise it, and the FDA advisory committee takeaways explain why a favorable committee vote did not turn an online vial into an approved or appropriately compounded medication.
A clinic that wants to offer peptide therapy has two lawful products to choose from: an FDA-approved drug, or a preparation compounded by a licensed pharmacy from a qualifying bulk substance. Before you order or prescribe any peptide, run four checks.
Peptavo's course teaches the full sourcing module, including how to vet pharmacies and read what FDA publishes, alongside accredited peptide CME. For the broader picture, start with the US legality guide, the guide to who can prescribe peptides, and our checklist for adding peptide therapy to your practice.
No. A research use only product is not an approved drug and not a lawful compounded preparation. Alabama, Mississippi, and South Carolina have each told licensees that prescribing, administering, dispensing, recommending, or supplying these products is prohibited, and FDA treats them as unapproved new drugs when they are intended for human use.
No. Buying a product labeled not for human use in order to give it to patients is the supplying the boards prohibit. Alabama and Mississippi also require providers to buy drugs and ingredients only from entities their board of pharmacy permits.
No. Alabama says a provider cannot "require or permit a patient to 'waive'" the duty of care, and that consent forms identifying a product as research grade do not reduce the provider's liability. Mississippi and South Carolina say the same.
No. Alabama says no CNM, CRNP, or PA is authorized to prescribe, administer, advise on, or dispense a research grade peptide because none is on an approved formulary, and South Carolina extends its notice to APRNs and PAs. A physician cannot delegate the task to get around the rule.
A compounded peptide is made by a licensed pharmacy for one identified patient, from a bulk substance that must meet section 503A and come from an FDA-registered manufacturer with a certificate of analysis. A research use only peptide is sold as a laboratory chemical with no patient, no prescription, and no oversight of its contents.
FDA's warning letters turn on intent. Once a seller markets a product for human use, or it is used in human administration, FDA treats it as an unapproved new drug whatever the label says. This page explains how prescribers should treat these products and is not purchasing advice.
Counsel the patient on the risks, document the conversation, and offer an approved or properly compounded option where one is clinically appropriate. Do not recommend, supply, or administer the product, and ask counsel before you monitor or adjust around a self-sourced regimen.
| Research grade peptides may not be used in patient care. The notice also flags marketed salt forms and research grade powders of a popular GLP-1 drug and says only prescription quality powder belongs in compounding. |